Oncology Central

Ixazomib recommended for NHS use for multiple myeloma

Ixazomib has been recommended for NHS distribution, to be used in combination with two other standard medications for the treatment of multiple myeloma patients who have received two or three prior lines of therapy.

The announcement comes after Phase III trials conducted by Takeda (High Wycombe, UK) demonstrated an improved progression-free survival rate of approximately 9 months with the oral IRd combination (ixazomib with lenalidomide and dexamethasone) , compared to standard therapeutics, lenalidomide and dexamethasone.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.